Sintilimab Versus Pembrolizumab for Advanced-stage Non-Small-Cell Lung Cancer

Summary

This study is a single-center, randomized controlled, phase II clinical trial, aiming at giving a comparison of Sintilimab and Pembrolizumab in stage IIIB-IV NSCLC patients at first-line treatment setting.

Timeline

Start

2020-03-01

Primary completion

2021-03-01

Completion

2021-12-01

Outcome

Met primary endpoint

paper and met its primary endpoint, with a confirmed ORR of 51.4% (18/35) in the sintilimab arms. PMID 38185589 ↗

Publications

• Maggie Liu SY, Huang J, Deng JY, Xu CR, Yan HH, Yang MY, Li YS, Ke EE, Zheng MY, Wang Z, Lin JX, Gan B, Zhang XC, Chen HJ, Wang BC, Tu HY, Yang JJ, Zhong WZ, Li Y, Zhou Q, Wu YL. PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trial. Sci Bull (Beijing). 2024 Feb 26;69(4):535-543. doi: 10.1016/j.scib.2023.12.046. Epub 2023 Dec 26.

Drugs

Indications